The OCMX™ is pleased to announce the listing of Tactical Therapeutics, Inc to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

NEW YORK, NY, June 15, 2018 /24-7PressRelease/ — Tactical Therapeutics, Inc is a clinical stage bio-pharma privately funded company that has developed a patented therapeutic, Carboxyamidotriazole Orotate (CTO), for treatment of glioblastomas and solid tumors.

The prognosis for glioblastoma patients is dismal, and current therapy with surgery, chemo-radiation and chemotherapy achieves a median overall survival (OS) of 16 to 18 months in newly diagnosed patients. There is a critical need for good drugs. The company has been in news world-wide since the publication of the results of CTO in Phase IB trial in forty-two glioblastoma patients.

The results reported in the prestigious journal, Journal of Clinical Oncology show promising proof-of-concept and clinical effects in Glioblastomas having multiple types of genomic mutations and even in the chemo-resistant tumors. Remarkably, CTO treated glioblastoma patients demonstrated significantly longer overall survival of twenty -eight months- mean OS was not reached since some patients remain on CTO with complete response at five years.

Four Phase I trials in one hundred patients have been completed, and two Phase II trials are planned for rGBM and nGBM. The company was granted Orphan Drug Designation for CTO and the company is pursuing partnering, co-development and/or licensing strategies to ensure rapid approval of CTO to benefit GBM patients in need.

The OCMX™ is pleased to announce the listing of Tactical Therapeutics, Inc to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on Tactical Therapeutics, Inc and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that Tactical Therapeutics, Inc exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

Rashida A. Karmali, JD, Ph.D., MBA, CEO and President | Dr. Karmali is Founder of TTI, Lead Scientist, Innovator, respected pioneer in cancer research. She is a registered patent and business lawyer specializing in drug discovery and development.

After the Ph. D in Biochemistry she developed a strong Cancer Research Program and worked at Memorial Sloan-Kettering in New York. Pursuing a part-time law degree, she next became a Registered Patent lawyer. She worked at leading firms in New York. She started a Solo-Law practice in Technology Law & Intellectual Property in 2000 and still runs it.

During her practice as a patent lawyer, she helped a client obtain a patent for a cancer drug (CTO), and eventually acquired its rights to develop it. Tactical Therapeutics was formed in 2005 and to reduce toxicity of the CTO acquired, a new process using different ingredients was developed. The resulting CTO crystals have no toxicity and better chemical characteristics which qualify this CTO as a new medical entity and a patentable drug.

The company’s philosophy is to develop cost effective, safe and efficacious drugs, and overcome resistance in cancers. The first target chosen to develop CTO is for glioblastoma a difficult to treat brain cancer, for which there is a critical need for drugs. The Clinical development of CTO in Glioblastoma patients has progressed with encouraging clinical results in Phase IB studies by improving the overall survival.

Dr. Karmali is planning to start two registration trials in glioblastoma patients to get CTO approved as an Orphan Drug on the fast track to fulfill the unmet need for good drugs in GBM.


The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

For the original version of this press release, please visit here